{"id":649,"date":"2026-06-30T12:35:00","date_gmt":"2026-06-30T16:35:00","guid":{"rendered":"https:\/\/drugchatter.com\/insights\/?p=649"},"modified":"2026-05-21T22:45:38","modified_gmt":"2026-05-22T02:45:38","slug":"when-ai-gives-off-label-drug-advice-what-pharma-must-track-now","status":"publish","type":"post","link":"https:\/\/drugchatter.com\/insights\/when-ai-gives-off-label-drug-advice-what-pharma-must-track-now\/","title":{"rendered":"When AI Gives Off-Label Drug Advice: What Pharma Must Track Now"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

A patient asks ChatGPT whether their antidepressant can help with chronic pain. Another asks Gemini if a GLP-1 drug will work for fatty liver disease. A third asks Perplexity which dose of a beta-blocker is safe for performance anxiety. None of these questions involve a doctor. All of them get answers.<\/p>\n\n\n\n

AI chatbots are now the first stop for medical questions that used to go to a physician, a pharmacist, or at minimum a credentialed health website. The answers they give are often accurate, sometimes outdated, occasionally fabricated, and almost never FDA-approved. For pharmaceutical companies, this creates a problem that sits at the crossroads of pharmacovigilance, brand management, and regulatory compliance \u2014 and most drug makers are not yet equipped to handle it.<\/p>\n\n\n\n

This article examines what happens when LLMs give off-label advice about prescription drugs, how those outputs create regulatory and reputational risk, and what pharmaceutical brand teams can do to monitor and respond before the FDA does it for them.<\/p>\n\n\n\n

\n\n\n\n

How AI Chatbots Became Unofficial Drug Reference Tools<\/strong><\/h2>\n\n\n\n

The shift happened faster than most pharmaceutical executives expected. Patients and caregivers began using ChatGPT, Claude, Gemini, and Perplexity as medical consultants within months of these products launching. The queries are not abstract. They are specific, personal, and often high-stakes.<\/p>\n\n\n\n

Search data and published research confirm the pattern. A 2023 study in JAMA Internal Medicine<\/em> found that ChatGPT outperformed physicians in measures of empathy and information quality when answering patient questions on Reddit’s r\/AskDocs \u2014 which was widely misread as an endorsement of AI medical advice rather than a warning about how patients were already using it.<\/p>\n\n\n\n

By 2024, use had accelerated. Surveys from the Pew Research Center showed that roughly one in five American adults had used an AI chatbot for health information. That number tracks higher among adults under 40, among patients with chronic conditions, and among people without easy access to primary care.<\/p>\n\n\n\n

Pharmaceutical companies spend hundreds of millions of dollars shaping how physicians think about their drugs. They have spent comparatively little thinking about how AI systems describe those same drugs \u2014 and even less on what happens when those descriptions are wrong or unapproved.<\/p>\n\n\n\n

Which AI Platforms Are Patients Actually Using for Drug Questions?<\/strong><\/h3>\n\n\n\n

ChatGPT commands the largest share of AI-mediated health queries by volume, driven by its consumer penetration and the integration of GPT-4 into Microsoft’s Bing search and Copilot products. Gemini has grown significantly inside Google Search through its AI Overviews feature, which now appears at the top of results for a wide range of drug-related queries. Claude handles a smaller but notable share of health queries and tends to apply more conservative language around medical advice. Perplexity has carved out a specific niche among patients who want sourced answers to medical questions \u2014 its citation model creates the appearance of evidence-based responses, whether or not the underlying citations are used correctly.<\/p>\n\n\n\n

Each platform generates different outputs for identical drug queries. Brand teams need to test them all.<\/p>\n\n\n\n

\n\n\n\n

What ‘Off-Label’ Actually Means in an AI Context<\/strong><\/h2>\n\n\n\n

Off-label use refers to prescribing an FDA-approved drug for an indication, population, or dosage not included in its approved labeling. The practice is legal \u2014 physicians can and regularly do prescribe drugs off-label based on clinical evidence. What is not legal is for pharmaceutical companies to promote those uses. FDA regulations under 21 CFR Part 202 and related guidance restrict manufacturers from disseminating promotional materials that suggest off-label applications, directly or indirectly.<\/p>\n\n\n\n

AI chatbots occupy a regulatory gray zone that is currently undefined. They are not pharmaceutical manufacturers. They are not physicians. They are not health publishers in any traditional sense. But they are recommending off-label uses to patients at scale, often in response to queries that originate from branded drug names.<\/p>\n\n\n\n

The question pharmaceutical legal and regulatory teams need to answer is not whether AI off-label advice is legal. It’s whether the company has any responsibility when an AI system trained partly on its own published materials recommends an unapproved use \u2014 and what the company’s liability exposure looks like when a patient acts on that advice.<\/p>\n\n\n\n

How LLMs Learn What Drugs Do (and Get It Wrong)<\/strong><\/h3>\n\n\n\n

Large language models do not consult the FDA label before answering a drug question. They generate responses based on patterns in their training data \u2014 a corpus that includes academic papers, clinical trial summaries, medical forums, patient advocacy sites, news articles, prescribing information scraped from the web, and yes, pharmaceutical company materials.<\/p>\n\n\n\n

The result is a model that sometimes knows the approved use, sometimes knows the off-label use, sometimes confuses the two, and sometimes produces confident-sounding answers that are simply wrong. The ratio of accurate to inaccurate depends on the drug’s profile, how much has been written about it, how recently that writing was produced, and how the model’s training data was curated.<\/p>\n\n\n\n

A drug like Ozempic (semaglutide) has been written about so extensively \u2014 in clinical literature, in media, in patient forums, and in direct-to-consumer advertising \u2014 that AI systems tend to produce relatively accurate core descriptions. A drug like tafenoquine (Krintafel, AstraZeneca) for malaria prophylaxis has a thinner public footprint and is more susceptible to incomplete or garbled AI responses.<\/p>\n\n\n\n

The Hallucination Problem: When AI Invents Drug Facts<\/strong><\/h3>\n\n\n\n

Hallucination is the term used to describe AI-generated text that is factually incorrect but presented with apparent confidence. In pharmaceutical contexts, hallucination is not a minor nuisance. It can constitute actionable misinformation about drug safety, efficacy, dosing, or contraindications.<\/p>\n\n\n\n

Documented examples from public AI testing include: ChatGPT citing a non-existent clinical trial to support a drug’s use in a pediatric population; Gemini stating an incorrect maximum daily dose for a widely prescribed anticoagulant; Perplexity attributing a cardiovascular safety signal to the wrong drug in a class comparison; Claude citing a drug interaction that contradicts the package insert. None of these systems flagged their own errors.<\/p>\n\n\n\n

For pharmaceutical companies, a hallucinated adverse event or a fabricated contraindication attached to their branded product carries real risk \u2014 reputational if it spreads, regulatory if it influences prescribing patterns or patient behavior in ways that lead to adverse outcomes.<\/p>\n\n\n\n

\n\n\n\n

Can AI Hallucinations Trigger FDA Pharmacovigilance Requirements?<\/strong><\/h2>\n\n\n\n

This is the question that pharmaceutical regulatory affairs teams have been debating since 2023, and it does not yet have a definitive answer from the FDA. What is clear is that adverse event reporting requirements under 21 CFR Part 314.81 cover information a manufacturer receives about adverse drug experiences, including from published literature and unpublished sources. Whether an AI-generated adverse event claim counts as reportable information is legally unsettled.<\/p>\n\n\n\n

The more immediate risk is indirect. If an AI chatbot recommends an off-label use for a drug and a patient experiences an adverse event while using it for that purpose, the chain of causation runs through the AI system, not through the manufacturer. But if that manufacturer’s own promotional materials, patient-facing content, or training data contributions shaped the AI’s response, the legal exposure calculus changes.<\/p>\n\n\n\n

The FDA has issued draft guidance on AI in drug development and manufacturing but has not yet issued specific guidance on AI-mediated off-label communications. The European Medicines Agency has been somewhat more proactive, flagging AI-generated health misinformation as an emerging regulatory concern in its 2024 workplan. Neither agency has finalized enforcement frameworks.<\/p>\n\n\n\n

FDA Warning Letters and AI: What’s Already Happened<\/strong><\/h3>\n\n\n\n

The FDA issued warning letters to several pharmaceutical companies between 2022 and 2024 related to social media and digital promotional activities. None specifically cited AI-generated content as the violation, but the underlying theory of liability \u2014 that manufacturers bear responsibility for third-party amplification of off-label claims \u2014 applies directly to AI systems.<\/p>\n\n\n\n

Notably, the FDA’s 2023 warning letter to Exactech regarding orthopedic device marketing included language about “misleading impressions” created through digital channels. The Office of Prescription Drug Promotion (OPDP) has signaled in public comments that it is monitoring AI-generated drug content and evaluating how existing promotional regulations apply.<\/p>\n\n\n\n

Pharmaceutical companies that wait for formal FDA guidance before building AI monitoring programs are taking a calculated risk. Regulators typically act after an incident, not before one. The companies that have already built systematic AI monitoring programs will be positioned to demonstrate proactive compliance. The ones that haven’t will be explaining why they didn’t.<\/p>\n\n\n\n

What Counts as a Spontaneous Adverse Event Report When the Source Is an AI?<\/strong><\/h3>\n\n\n\n

ICH E2D guidelines define a valid individual case safety report as requiring an identifiable patient, an identifiable reporter, a suspect drug, and an adverse event. An AI chatbot response is not a case report in any conventional sense. But pharmacovigilance teams at major pharmaceutical companies have begun asking whether patterns in AI-generated adverse event mentions \u2014 clustered around specific drugs, specific off-label uses, specific populations \u2014 constitute a signal that should be entered into their safety surveillance systems.<\/p>\n\n\n\n

The answer, most pharmacovigilance professionals agree, is: not yet formally required, but probably smart to track. If AI systems are consistently associating a branded drug with a safety concern not in the label, that pattern is signal-worthy regardless of whether it meets ICH reporting thresholds.<\/p>\n\n\n\n

\n

‘AI search platforms are now generating more drug-related responses per day than the entire published literature base accumulated over the last decade. The pharmacovigilance frameworks we have were built for a world where drug information moved slowly. That world is gone.’ \u2014 Scott Brunner, former CEO, Alliance for Pharmacy Compounding, speaking at DIA 2024.<\/p>\n<\/blockquote>\n\n\n\n

\n\n\n\n

How Often Do LLMs Recommend Off-Label Uses? A Look at the Data<\/strong><\/h2>\n\n\n\n

Systematic studies of LLM off-label recommendations are limited but growing. A 2024 paper in npj Digital Medicine<\/em> tested five major LLMs \u2014 GPT-4, Gemini Pro, Claude 2, Llama 2, and Mistral \u2014 against a panel of 100 drug queries covering approved and off-label uses. The study found that LLMs recommended or described off-label uses in 41% of responses, without consistently flagging that the use was unapproved.<\/p>\n\n\n\n

GPT-4 was most likely to include a disclaimer noting that a use was off-label or not FDA-approved. Claude was most likely to decline to make a specific recommendation and redirect to a healthcare provider. Gemini Pro and Llama 2 were most likely to describe off-label mechanisms and dose ranges without caveat. Mistral produced the highest rate of factually incorrect information about drug mechanisms.<\/p>\n\n\n\n

These patterns matter for brand teams because they indicate that the same drug query produces different risk profiles depending on which AI platform a patient uses. A brand team tracking only ChatGPT outputs is missing the Gemini population \u2014 which may be larger, given Google’s search volume dominance.<\/p>\n\n\n\n

Which Drug Classes See the Most AI Off-Label Recommendations?<\/strong><\/h3>\n\n\n\n

Weight loss and metabolic drugs generate the highest volume of off-label AI queries by a wide margin. Semaglutide drugs (Ozempic, Wegovy, Rybelsus) are asked about for uses ranging from PCOS treatment to alcoholism reduction to Alzheimer’s disease risk reduction \u2014 most of which are the subject of active research but are not FDA-approved indications. Tirzepatide (Mounjaro, Zepbound) faces similar dynamics.<\/p>\n\n\n\n

ADHD medications, particularly amphetamine-based formulations like Adderall (Teva) and lisdexamfetamine (Vyvanse, Takeda\/Shire), are heavily queried for off-label cognitive enhancement and weight management uses. Antidepressants \u2014 especially bupropion (Wellbutrin, GSK) and mirtazapine \u2014 are frequently asked about for off-label indications including smoking cessation, weight management, and sexual dysfunction.<\/p>\n\n\n\n

Psychiatric medications generally see high rates of off-label AI engagement. Ketamine-based drugs including esketamine (Spravato, Janssen) are discussed by AI systems in contexts of treatment-resistant depression sub-types not specifically covered by the label. Quetiapine (Seroquel, AstraZeneca) continues to generate off-label AI queries for insomnia, a use widely practiced despite lacking FDA approval for that indication.<\/p>\n\n\n\n

How Claude Handles Drug Questions Differently Than ChatGPT<\/strong><\/h3>\n\n\n\n

Claude, built by Anthropic, takes a noticeably more conservative posture on drug recommendation queries than GPT-4. When asked about off-label uses, Claude typically acknowledges the clinical discussion around a use, notes that it is not FDA-approved for that indication, and directs the user to a prescribing physician before providing specific dosing information. This behavior is consistent but not absolute \u2014 it degrades when queries are framed as hypothetical, when the user provides a clinical justification, or when the query is embedded in a longer conversation where context has accumulated.<\/p>\n\n\n\n

ChatGPT with the default GPT-4 configuration is more variable. It frequently provides dosing information for off-label uses with caveats that are easy to miss or ignore. Gemini’s behavior sits between these two poles. Perplexity often produces the most clinically detailed responses because its citation-retrieval architecture surfaces primary literature directly \u2014 which can include papers describing off-label uses in clinical trial populations that patients may not accurately interpret as non-approved.<\/p>\n\n\n\n

None of these behavioral profiles are static. Each platform updates its models regularly, and brand teams that characterized a platform’s behavior in Q1 may find it substantively different in Q3.<\/p>\n\n\n\n

\n\n\n\n

What Pharma Brand Teams Can Learn From Monitoring AI Search Outputs<\/strong><\/h2>\n\n\n\n

The pharmaceutical industry has spent the last two decades building social listening programs to monitor patient sentiment on forums, Reddit, Twitter\/X, and condition-specific communities. AI search outputs represent a new category of signal that requires different monitoring infrastructure but produces similarly actionable intelligence.<\/p>\n\n\n\n

When a pharmaceutical brand team systematically queries ChatGPT, Gemini, Claude, and Perplexity with the same inputs their target patients and physicians are using, they collect four types of intelligence simultaneously: competitive positioning data, safety signal data, patient perception data, and off-label discussion data.<\/p>\n\n\n\n

Tools purpose-built for this task have emerged. DrugChatter<\/a> focuses specifically on pharmaceutical AI monitoring, allowing brand teams to track how LLMs discuss their drugs, compare responses across platforms, identify off-label mentions, and flag potential hallucinated safety claims. This kind of purpose-built infrastructure matters because general social listening tools are not designed to ingest and classify LLM outputs against FDA label language.<\/p>\n\n\n\n

Tracking Share of Voice Across ChatGPT, Gemini, and Claude<\/strong><\/h3>\n\n\n\n

Share of voice \u2014 the proportion of category mentions that reference your brand versus a competitor’s \u2014 has been a standard metric in pharmaceutical marketing for decades. AI search has created a new version of this metric that brand teams need to measure.<\/p>\n\n\n\n

When a patient asks an AI chatbot ‘what’s the best medication for Type 2 diabetes,’ the response constitutes an AI-mediated share-of-voice event. If the AI consistently mentions Jardiance (empagliflozin, Boehringer Ingelheim\/Eli Lilly) before Farxiga (dapagliflozin, AstraZeneca) in that context, Boehringer Ingelheim has a structural advantage in AI share of voice for that query cluster \u2014 regardless of what happens in physician detailing or traditional media.<\/p>\n\n\n\n

Measuring this consistently requires running standardized query sets across platforms on a scheduled basis, logging the outputs, and analyzing mention patterns over time. The methodology is closer to SEO rank tracking than to traditional brand tracking, but the business stakes are pharmaceutical-scale.<\/p>\n\n\n\n

Do LLMs Recommend Generic Drugs More Often Than Branded Drugs?<\/strong><\/h3>\n\n\n\n

The short answer is: sometimes, and inconsistently. LLMs trained on publicly available medical literature and prescribing guidelines tend to reflect the evidence-based medicine norm, which favors cost-effective prescribing and often defaults to generics when bioequivalence is established. Academic medical center guidelines, which heavily influence AI training data, frequently recommend generic first-line agents.<\/p>\n\n\n\n

For branded drugs without generic competition, this is not an immediate problem. For branded drugs competing with established generics \u2014 metformin versus branded diabetes drugs, generic statins versus branded alternatives, generic antidepressants versus on-patent variants \u2014 AI systems may be systematically directing patients and physicians toward generics in ways that pharmaceutical companies have no mechanism to track, let alone address.<\/p>\n\n\n\n

The dynamic is especially sharp for drugs in the GLP-1 class. There is currently no generic semaglutide \u2014 the FDA-approved Ozempic and Wegovy are Novo Nordisk-branded products, and compounded semaglutide products are a regulatory separate question. But when patients ask AI chatbots about ‘cheaper alternatives to Ozempic,’ the outputs are highly variable and sometimes medically problematic.<\/p>\n\n\n\n

How Patients Ask About Drug Interactions in AI Chat<\/strong><\/h3>\n\n\n\n

Drug interaction queries are among the highest-stakes AI health queries because the answers directly affect safety behavior. Patients routinely ask AI chatbots whether their prescriptions interact with alcohol, supplements, other medications, or over-the-counter drugs. These queries often involve drugs where the interaction information in AI training data is incomplete, outdated, or incorrectly generalized from class-level to drug-level data.<\/p>\n\n\n\n

A concrete example: queries about serotonin syndrome risk when combining SSRIs with triptans produce significantly different outputs across AI platforms. The FDA has issued specific guidance on this interaction. Some AI systems accurately convey the guidance; others overstate the risk; others understate it. Patients who act on inaccurate information about either direction of the error face real clinical consequences.<\/p>\n\n\n\n

For pharmaceutical companies whose drugs are frequently involved in interaction queries, monitoring AI outputs for those specific interaction pairs is a pharmacovigilance-adjacent function that sits in an organizational gap between medical affairs, safety, and brand marketing. Someone needs to own it.<\/p>\n\n\n\n

\n\n\n\n

How Eli Lilly and Novo Nordisk Are Thinking About AI Monitoring<\/strong><\/h2>\n\n\n\n

Neither Eli Lilly nor Novo Nordisk has published detailed public disclosures of their AI monitoring programs. What is available through conference presentations, job postings, and trade press coverage suggests both companies have moved beyond ad hoc monitoring into structured programs \u2014 though neither would describe what they have as fully mature.<\/p>\n\n\n\n

Eli Lilly, whose GLP-1 franchise (tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss) generates enormous AI search volume, has publicly invested in digital health intelligence capabilities. The company’s digital marketing and patient experience teams have been hiring for roles that include monitoring AI-generated content about their products since at least 2023. Given the volume of misinformation circulating about compounded tirzepatide and the off-label overlap between the Mounjaro and Zepbound indications, the monitoring imperative is clear.<\/p>\n\n\n\n

Novo Nordisk faces a different version of the same problem. Semaglutide is discussed in AI systems across at least a dozen potential indications \u2014 obesity, Type 2 diabetes, PCOS, non-alcoholic steatohepatitis, cardiovascular risk reduction, Alzheimer’s disease (investigational), addiction reduction (investigational), and others. Each of those discussions carries different label implications, different patient populations, and different regulatory risk profiles. Monitoring all of them across all major AI platforms is not a small task.<\/p>\n\n\n\n

Novo Nordisk’s 2024 litigation against compounding pharmacies producing semaglutide copies illustrates the broader enforcement environment that pharmaceutical companies operate in. AI chatbots that direct patients toward compounded semaglutide alternatives \u2014 which several have done \u2014 are participating, knowingly or not, in a supply chain that Novo Nordisk is simultaneously fighting in federal court.<\/p>\n\n\n\n

What a Systematic AI Monitoring Program Looks Like in Practice<\/strong><\/h3>\n\n\n\n

A mature pharmaceutical AI monitoring program has four functional components: query design, output capture, classification, and reporting.<\/p>\n\n\n\n

Query design means building a library of natural-language prompts that reflect how patients, caregivers, and physicians actually ask about your drugs. This is not the same as keyword lists. It requires qualitative research \u2014 listening to what questions are being asked in patient communities, on Reddit, in call center transcripts, and in patient support programs \u2014 and translating those into AI-testable query sets.<\/p>\n\n\n\n

Output capture means systematically running those queries across target AI platforms on a defined schedule \u2014 weekly at minimum, daily for high-priority drugs \u2014 and logging the raw outputs with metadata including platform, model version, date, and query text. Version tracking matters because AI models are updated frequently, and a response pattern that was stable can change overnight with a model update.<\/p>\n\n\n\n

Classification means processing outputs against a defined schema: Is the use described on-label or off-label? Is safety information accurate? Are competitor drugs mentioned? Is there a hallucinated claim? Does the output recommend professional consultation? Classification can be done manually for small drug portfolios; at scale, it requires NLP tooling or AI-assisted review.<\/p>\n\n\n\n

Reporting means routing intelligence to the right internal stakeholders: safety signals to pharmacovigilance, off-label discussions to regulatory and legal, competitive mentions to brand marketing, patient sentiment data to patient affairs and market research. The routing protocols need to be defined in advance, or the data sits in a monitoring team’s inbox with no actionable outcome.<\/p>\n\n\n\n

\n\n\n\n

AI-Generated Medical Misinformation and the Liability Exposure It Creates<\/strong><\/h2>\n\n\n\n

The liability landscape for AI-generated medical misinformation is evolving rapidly. Three legal theories are currently being tested across various types of AI harm litigation, and all three have potential application to pharmaceutical contexts.<\/p>\n\n\n\n

The first is product liability. If an AI system is considered a product \u2014 a position some courts and scholars argue for \u2014 then manufacturers of that AI system may bear strict liability for defects in their outputs, including medically inaccurate drug advice. OpenAI, Google, Anthropic, and other AI developers have been proactive in structuring their terms of service to disclaim medical advice liability, but terms of service disclaimers have historically not fully insulated technology companies from product liability claims.<\/p>\n\n\n\n

The second is negligence. A negligence theory would require showing that an AI company had a duty to ensure medically accurate outputs, breached that duty, and that the breach caused harm. This is a harder path because duty is contested, but it is not foreclosed \u2014 particularly as AI systems are marketed with increasing specificity for health and medical use cases.<\/p>\n\n\n\n

The third, and most directly relevant to pharmaceutical companies, is contribution or concert of action. If a pharmaceutical company’s promotional materials, patient education content, or submitted clinical data contributed to an AI system’s training in ways that shaped inaccurate off-label representations, the manufacturer could face claims that it contributed to the harm. This theory has not been litigated in the AI context, but it echoes theories that have been used successfully against pharmaceutical companies in ghostwriting and off-label promotion cases.<\/p>\n\n\n\n

Precedents From Social Media Off-Label Promotion Cases<\/strong><\/h3>\n\n\n\n

The pharmaceutical industry has been here before in a different form. Between 2009 and 2019, the FDA and DOJ pursued a series of major enforcement actions against pharmaceutical companies for off-label promotion through digital channels and third-party communications.<\/p>\n\n\n\n

Allergan paid $600 million in 2010 to resolve DOJ allegations that it promoted Botox for off-label uses. GlaxoSmithKline’s $3 billion settlement in 2012 \u2014 still the largest healthcare fraud settlement in history at the time \u2014 included off-label promotion of Paxil (paroxetine) and Wellbutrin (bupropion) as a core allegation. Jazz Pharmaceuticals paid $57 million in 2021 to resolve allegations related to off-label promotion of Xyrem (sodium oxybate).<\/p>\n\n\n\n

None of these cases involved AI. All of them involved the principle that manufacturers are accountable for the downstream effects of off-label promotional activity, even when that activity is mediated through third parties or indirect channels. The application to AI monitoring is: you need to know what AI systems are saying about your drug, because if what they’re saying derives from your content and causes harm, the regulatory and legal framework suggests you may be asked to answer for it.<\/p>\n\n\n\n

How Reddit AI Citations Affect Patient Behavior Around Drug Use<\/strong><\/h3>\n\n\n\n

One undermonitored dynamic is the feedback loop between Reddit and AI systems. Patient communities on Reddit \u2014 r\/diabetes, r\/loseit, r\/ADHD, r\/bipolar, r\/ChronicPain, and dozens of others \u2014 are among the highest-signal sources of real-world patient drug experience available anywhere. These communities discuss off-label uses extensively, share personal dosing protocols, report adverse experiences, and compare branded and generic products in granular detail.<\/p>\n\n\n\n

AI systems trained on public Reddit data have absorbed this community knowledge and reproduce it in responses to user queries. When a patient asks Perplexity about using low-dose naltrexone (LDN) for chronic fatigue syndrome \u2014 an off-label use with active patient community discussion but no FDA-approved indication \u2014 the response may draw on years of Reddit posts from patients who have tried it, positive and negative. The patient gets what feels like community wisdom, filtered through AI, without the context that it is a community of patients self-experimenting outside approved medical guidance.<\/p>\n\n\n\n

Pharmaceutical companies that are not monitoring the patient communities that seed AI training data are missing a significant early-warning system for emerging off-label use patterns and safety signals.<\/p>\n\n\n\n

\n\n\n\n

Voice-of-the-Customer Intelligence From AI Queries: What Brand Teams Are Missing<\/strong><\/h2>\n\n\n\n

The queries patients type into AI chatbots are primary market research data. They reveal unmet needs, confusion about existing drugs, concerns about side effects, questions about comparative efficacy, and anxieties about cost \u2014 all in natural language, unsolicited, and at enormous scale.<\/p>\n\n\n\n

Traditional voice-of-the-customer research \u2014 focus groups, patient surveys, advisory boards \u2014 is expensive, slow, and subject to social desirability bias. Patients in focus groups often report what they think researchers want to hear. Patients asking an AI chatbot at 11pm about whether their medication is causing their fatigue are revealing exactly what they think, to no social audience.<\/p>\n\n\n\n

The intelligence is actionable across multiple business functions. Brand teams can identify messaging gaps \u2014 where patients are confused about a drug’s mechanism or appropriate use \u2014 and address them in patient education materials. Medical affairs teams can identify emerging off-label interest that might warrant additional clinical research. Patient support programs can identify high-frequency concerns that suggest unmet patient needs. Regulatory teams can identify AI-generated safety signals that may warrant label updates or Dear Healthcare Provider letters.<\/p>\n\n\n\n

None of this intelligence is currently being systematically captured by most pharmaceutical companies. The monitoring infrastructure exists \u2014 it needs to be applied to AI outputs. Services like DrugChatter<\/a> are built specifically to translate raw AI outputs into structured pharmaceutical intelligence, removing the manual analytical burden from already-stretched brand teams.<\/p>\n\n\n\n

How Physicians Are Using AI to Look Up Drug Information<\/strong><\/h3>\n\n\n\n

The patient-facing AI risk is well-publicized. The physician-facing risk is less discussed but potentially more consequential, because physician queries result in prescribing decisions.<\/p>\n\n\n\n

Surveys published in JAMA and the New England Journal of Medicine<\/em> in 2023 and 2024 found that a significant and growing proportion of physicians use AI tools to research drug information \u2014 for mechanisms, dosing, interactions, and off-label evidence. A 2024 survey of primary care physicians found that 34% had used an AI chatbot to help answer a clinical question in the prior 30 days. The proportion was higher among physicians under 40.<\/p>\n\n\n\n

The implications are direct. If an AI system provides a physician with incorrect information about a drug’s dosing in a specific population \u2014 say, renal dosing adjustments for an antibiotic \u2014 and the physician prescribes accordingly, the AI has directly influenced an adverse outcome. The pharmaceutical company whose drug was involved has an interest in ensuring AI systems represent their product’s prescribing information accurately, not only for patient-safety reasons but because adverse events resulting from AI misinformation will appear in their pharmacovigilance data.<\/p>\n\n\n\n

What Happens When AI Recommends a Competitor Drug First?<\/strong><\/h3>\n\n\n\n

Brand teams that have tested AI chatbot responses to competitive queries \u2014 ‘what’s the best drug for X condition’ \u2014 have found significant variation in which drugs are mentioned, in what order, with what level of enthusiasm, and with what caveats. These outputs are not random. They reflect patterns in training data, which reflects patterns in published medical literature, prescribing guidelines, media coverage, and patient discussion.<\/p>\n\n\n\n

A drug that is heavily discussed in high-quality clinical literature, that has favorable mentions in major prescribing guidelines, and that has a strong patient community presence will tend to be mentioned more frequently and more favorably by AI systems. A drug that is newer, less studied, or that has received negative media coverage may be systematically disadvantaged in AI outputs regardless of its clinical profile.<\/p>\n\n\n\n

This creates a direct line between a pharmaceutical company’s medical affairs strategy \u2014 its investment in publication, guideline development, and key opinion leader relationships \u2014 and its AI share of voice. Medical affairs decisions made today will shape what AI systems say about your drug in 18 to 24 months, once new publications enter training data.<\/p>\n\n\n\n

\n\n\n\n

Building an AI Monitoring Infrastructure: Where to Start<\/strong><\/h2>\n\n\n\n

Most pharmaceutical companies approaching this for the first time face the same question: where does this live organizationally? The honest answer is that AI monitoring sits at the intersection of several functions that rarely collaborate natively \u2014 digital marketing, medical affairs, pharmacovigilance, regulatory, and legal. That organizational complexity is the primary reason most companies have not yet built a systematic program.<\/p>\n\n\n\n

The path that works in practice is to start with a defined pilot scope \u2014 one or two priority brands, the four major AI platforms (ChatGPT, Gemini, Claude, Perplexity), a defined query library, and a quarterly reporting cadence \u2014 and build from there. The pilot generates internal evidence of value that justifies the organizational investment to scale.<\/p>\n\n\n\n

The query library for a pilot should cover at minimum: approved indications (to verify accurate representation), known off-label uses (to identify AI off-label content), key safety topics (to verify accurate adverse event representation), common patient confusion points (to identify messaging gaps), and competitive positioning queries (to establish share-of-voice baseline).<\/p>\n\n\n\n

Platforms like DrugChatter<\/a> accelerate this process by providing pre-built monitoring infrastructure specifically designed for pharmaceutical use cases, including label-aware classification and regulatory-grade output logging \u2014 capabilities that general social listening tools do not provide.<\/p>\n\n\n\n

What to Do When You Find an AI Hallucination About Your Drug<\/strong><\/h3>\n\n\n\n

Finding an AI hallucination about your drug raises the question of what, if anything, you can do about it. The options are more limited than most brand teams expect, and the appropriate response depends on the nature of the hallucination.<\/p>\n\n\n\n

For factual errors about mechanism of action or approved indication, the most effective long-term intervention is publication strategy \u2014 ensuring that accurate, well-structured information about your drug is available in formats that are likely to enter future AI training data. Company newsroom content, peer-reviewed publications, and regulatory submission documents are all potential training data sources. The FDA label itself is almost universally present in AI training corpora, but model updates and context window limitations mean it is not always faithfully reproduced in outputs.<\/p>\n\n\n\n

For hallucinated safety signals \u2014 AI systems attributing adverse events to your drug that are not in the label \u2014 the response involves legal review of whether there is any promotional or contributory pathway that created the claim, pharmacovigilance review of whether the claim represents an actual emerging signal worth investigating, and potentially direct outreach to the AI platform to flag the factual error. Most major AI platforms have mechanisms for reporting medically inaccurate content, though response timelines are unpredictable.<\/p>\n\n\n\n

Direct outreach to platform trust-and-safety teams works better when it comes from a credentialed medical or regulatory professional with documented evidence of the inaccuracy. Generic brand team complaints are less effective.<\/p>\n\n\n\n

LLM Search Optimization for Pharmaceutical Brands: What It Is and What It Isn’t<\/strong><\/h3>\n\n\n\n

The SEO industry has begun talking about ‘LLM optimization’ or ‘GEO’ (generative engine optimization) \u2014 strategies for influencing how AI systems represent your brand or product. The pharmaceutical application is more constrained than the general commercial one, because pharmaceutical communications are subject to FDA promotional regulations that do not apply to consumer brands.<\/p>\n\n\n\n

What pharmaceutical companies can legitimately do: ensure that accurate, approved information about their drugs is published in high-quality, well-structured formats that AI training pipelines tend to favor \u2014 peer-reviewed journals, medical society guidelines, FDA-reviewed patient education materials, prescribing information pages with structured data markup. This is not manipulation of AI systems; it’s ensuring that the accurate information about your drug is available in the places AI systems look.<\/p>\n\n\n\n

What pharmaceutical companies should not do: attempt to flood AI training pipelines with promotional content designed to shape off-label discussions, or attempt to influence AI systems to recommend their products in contexts where promotional regulations would prohibit that recommendation from a human representative.<\/p>\n\n\n\n

\n\n\n\n

Specific Risk Scenarios: What Happens When It Goes Wrong<\/strong><\/h2>\n\n\n\n

Abstract risk discussions are less useful than concrete scenarios. Here are four specific risk scenarios that pharmaceutical companies have faced or are likely to face as AI health queries scale.<\/p>\n\n\n\n

Scenario 1: AI Recommends Off-Label Dosing That Causes Harm<\/strong><\/h3>\n\n\n\n

A patient asks an AI chatbot about using methotrexate for rheumatoid arthritis. The AI provides a dosing range that is accurate for oncology use of methotrexate but substantially higher than the doses used in rheumatological practice. The patient, misreading the response, takes a dose that causes severe toxicity. This scenario is not hypothetical \u2014 methotrexate dosing errors are among the most documented medication errors in pharmacy, and the difference between oncology and rheumatology dosing is exactly the type of context-dependent detail that AI systems handle poorly.<\/p>\n\n\n\n

Scenario 2: AI Attributes a Competitor’s Safety Signal to Your Drug<\/strong><\/h3>\n\n\n\n

A safety signal emerges for a drug in your therapeutic class \u2014 say, a cardiovascular risk associated with a competitor’s product. AI systems, trained on media coverage that sometimes conflates class effects with individual drug effects, begin associating the safety signal with your branded product as well. Patients and physicians asking AI chatbots about your drug get responses that include the competitor’s safety signal. Your brand is damaged by a hallucinated class association that the AI presents as fact.<\/p>\n\n\n\n

Scenario 3: AI Drives Patients to Compounded or Counterfeit Alternatives<\/strong><\/h3>\n\n\n\n

A patient asks an AI chatbot ‘where can I get Ozempic cheaper.’ The AI provides information about compounding pharmacies, international pharmacy options, or patient assistance programs \u2014 some of which are legitimate, some of which are not. The patient obtains a product that is either a compounded formulation or a counterfeit, experiences an adverse event, and the adverse event is reported against the branded semaglutide despite involving a non-Novo Nordisk product.<\/p>\n\n\n\n

Scenario 4: AI Off-Label Recommendation Becomes the Standard of Care Expectation<\/strong><\/h3>\n\n\n\n

AI systems consistently describe an off-label use for your drug \u2014 based on clinical trial data that exists but for which you have not sought approval \u2014 in sufficiently positive terms that patients begin arriving at physician appointments with AI-generated ‘evidence’ for the unapproved use. Physicians feel pressure to prescribe off-label based on patient expectations set by AI. If the drug causes adverse events in this off-label population, the manufacturer faces both pharmacovigilance obligations and potential liability, having never marketed for the use but having benefited commercially from AI-driven demand.<\/p>\n\n\n\n

\n\n\n\n

Regulatory Trajectory: Where FDA and EMA Are Headed<\/strong><\/h2>\n\n\n\n

The FDA’s Digital Health Center of Excellence has been the primary internal locus for thinking about AI in pharmaceutical contexts. Its 2023 action plan on AI\/ML-based software as a medical device addresses AI in diagnostics and monitoring but does not directly address AI search and chatbot outputs as a promotional or pharmacovigilance concern.<\/p>\n\n\n\n

The OPDP \u2014 the division that enforces pharmaceutical promotional regulations \u2014 has been more circumspect publicly, but its conference presentations and public comments have made clear that it considers existing promotional regulations applicable to AI-mediated communications, including cases where pharmaceutical content shapes AI outputs. The ‘truthful, balanced, and non-misleading’ standard for promotional communications does not have an AI exception.<\/p>\n\n\n\n

The EMA’s 2024 AI workplan explicitly flagged AI-generated health misinformation as a regulatory priority, with particular attention to social media and conversational AI. The EU AI Act, which came into force in phases starting in 2024, classifies AI systems providing health information as high-risk systems subject to enhanced transparency and accuracy requirements. This has direct implications for AI platforms operating in the EU that provide drug information \u2014 and indirect implications for pharmaceutical companies whose products are described by those systems.<\/p>\n\n\n\n

The trajectory is toward more regulatory engagement with AI-generated pharmaceutical content, not less. Companies building monitoring infrastructure now will have the data and the demonstrated diligence to navigate that regulatory engagement from a position of strength.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways<\/strong><\/h2>\n\n\n\n